Paul S. Aisen

This study tests a treatment called AADvac1, which targets tau protein tangles in the brain, a hallmark of Alzheimer's. It will be given alone or with another drug (donanemab) to 450 adults aged 50-80 with early-stage Alzheimer's. The goal is to see if it safely reduces tau build…

This study tests whether new drugs that target tau protein in the brain can slow or stop Alzheimer's disease in its early stages. About 900 adults aged 50 to 80 with very mild or no symptoms will receive a tau drug, a combination of a tau drug and donanemab, or donanemab alone. T…